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Abstract Tyrosine kinase inhibitors (TKIs) have dramat-
ically improved the life expectancy of patients suffering
from chronic myeloid leukemia (CML); however, pa-
tients will eventually develop resistance to TKI therapy
or adverse side effects due to secondary off-target
mechanisms associated with TKIs. CML patients
exhibiting TKI resistance are at greater risk of develop-
ing an aggressive and drug-insensitive disease. Drug-
resistant CML typically arises in response to spontane-
ous mutations within the drug binding sites of the
targeted oncoproteins. To better understand the mecha-
nism of drug resistance in TKI-resistant CML patients,
the BCR-ABL transformed cell line KCL22 was grown
with increasing concentrations of imatinib for a period
of 6 weeks. Subsequently, a drug-resistant derivative of
the parental KCL22 cell line harboring the T315I gate-
keeper mutation was isolated and investigated for TKI
drug sensitivity via multi-agent drug screens. A syner-
gistic combination of ponatinib- and forskolin-reduced
cell viability was identified in this clinically relevant
imatinib-resistant CML cell line, which also proved ef-
ficacious in other CML cell lines. In summary, this
study provides new insight into the biological underpin-
nings of BCR-ABL-driven CML and potential rationale
for investigating novel treatment strategies for patients
with T315I CML.
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Introduction
Chronic myeloid leukemia (CML) is characterized by the
presence of the Philadelphia (Ph) chromosome, a chromo-
somal abnormality arising from a translocation between
the long arms of chromosome 9 and chromosome 22
[1]. CML is a neoplasm that originates from the hemato-
poietic lineage that is categorized by three distinct phases.
The chronic phase (CP) is the most treatable and frequent-
ly diagnosed stage. The accelerated phase (AP) and blast
phase (BP) are the least commonly diagnosed stages and
represent end stage of the disease [2]. The Ph chromo-
some produces a constitutively active protein tyrosine ki-
nase, BCR-ABL. Over the past 15 years, BCR-ABL has
served as a hallmark for the identification of CML and
has been extensively studied as a key target in the devel-
opment of chemotherapies, such as imatinib.
Imatinib is an ATP-binding antagonist that interacts
with the P-loop/ATP binding site of the BCR-ABL protein.
Such binding renders BCR-ABL incapable of activating
downstream targets involved in pro-survival signaling
pathways such as Janus kinase (JAK), signal transducer
and activator of transcription (STAT), SRC family kinase
(SFK), phosphatidylinositol 3-kinase (PI3K), protein ki-
nase B (AKT), mitogen-activated protein kinase
(MAPK), and RAS signaling pathways [3]. Mortality rates
of patients with CML have been significantly reduced with
the introduction of imatinib as a therapeutic agent. In a trial
of 1503 patients treated with imatinib and monitored for
more than 10 years, the resulting progression-free survival
rate was 82 % [4]. Importantly, patients within this study
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also displayed an 84 % overall survival rate with little to no
adverse side effects associated with imatinib therapy [4].
Despite having high levels of success in treating CML with
imatinib, a significant percentage of CML patients go on to
develop drug toxicities or drug resistance resulting in an
increased risk of progressing towards the BP stage of
disease.
While the underlying mechanisms by which imatinib
sensitivity are lost are not entirely understood, it has
been reported that 90-point mutations within the BCR-
ABL protein comprise the majority of imatinib-resistant
CML cases [2]. Recently, second and third generation
tyrosine kinase inhibitors (TKIs), such as dasatinib and
nilotinib, have been approved to treat resistant forms of
CML and have exhibited marked success [5]. Dasatinib
can be used as a front-line treatment because of its abil-
ity to target SFK signaling pathways downstream of
BCR-ABL. However, somatic mutations in BCR-ABL
render the protein insensitive to nilotinib or dasatinib
treatment. The third-generation TKI, bosutinib, has
displayed limited therapeutic potential for treating CML
patients expressing somatic mutations found within the
BCR-ABL kinase domain, specifically the T315I muta-
tion [6].
Ponatinib, a third-generation TKI, was specifically de-
signed to inhibit BCR-ABL-positive CML cells containing
the T315I mutation. Ponatinib is a unique TKI which does
not require a hydrogen bond to the native threonine 315 res-
idue required by imatinib, nilotinib, and dasatinib to associate
with the BCR-ABL ATP-binding pocket [7]. Phase I clinical
trials of ponatinib in refractory Ph chromosome-positive leu-
kemias demonstrated high efficacy against multiple resistant
forms including those harboring the T315I mutation [8].
Ponatinib has also been demonstrated to be effective against
the T315I TKI-resistant CML cells; however, serious adverse
side effects such as blood clots and narrowing of blood vessels
were reported [9–11]. Patients receiving TKI therapy are at
increased risk of developing hypertension, arterial/venous
thromboembolic events, cerebral ischemia, or myocardial in-
farction due to secondary off-target effects of TKIs. Moreover,
CML patients with underlying conditions were found to be
more prone to develop adverse reactions such as pulmonary
hypertension, peripheral arterial occlusive disease, and venous
and arterial vascular occlusive events, if undergoing therapy
with second- and third-generation TKIs [12].
Given the limited number of treatment options avail-
able for drug-resistant CML patients, new avenues of TKI
utilization must be explored in order to reduce adverse
side effects associated with treatment and increase patient
survival. As such, the current study sought to investigate
TKI resistance and identify novel drug combinations with
biological and clinical rationale for the treatment of T315I
positive CML. The results provided herein suggest that a
two-compound combination of ponatinib and forskolin, a
natural chemical produced in the roots of the plant Coleus
forskohlii, works in a synergistic fashion to inhibit drug-
resistant CML.
Results
Generation and characterization of an imatinib-resistant
CML cell line harboring the BCR-ABLT315I mutation
Studies were conducted utilizing the human KCL22 cell
line, originally established from the pleural effusion of a
32-year-old female exhibiting Ph-positive CML during BP
stage of disease [13]. This cell line has been extensively
used as a model to investigate one of the most aggressive
stages of CML. Here, KCL22 cells were treated with in-
creasing concentrations of imatinib for 6 weeks as de-
scribed in the BMaterials and Methods^ section to generate
an imatinib-resistant CML, KCL22-IR, and cell line.
KCL22-IR cells were assessed for cell viability in response
to multiple FDA-approved kinase inhibitors, chromosomal
abnormalities, and mutations within the BCR-ABL coding
sequences (Fig. 1). Parental KCL22 (KCL22-WT) and
KCL22-IR cells were screened against 14 FDA-approved
kinase inhibitors at Cmax-derived dose points for 72 h.
Similarly, the unrelated but well-studied human CML cell
line, K562, was assessed using the Cmax inhibitory drug
concentrations. Following 72-h treatment, cell viability
was measured by MTS assay (Fig. 1a). The results indicate
that KCL22-IR cells are insensitive to treatment with the
majority of the kinase inhibitors used in the screen. Both
K562 and KCL22 parental cells displayed sensitivity to-
wards imatinib, dasatinib, nilotinib, and ponatinib as seen
by cell viability levels below 20 %. KCL22-IR cells
displayed a limited response against both BCR-ABL- and
non-BCR-ABL-selective inhibitors such as sunitinib,
nilotinib, trametinib, temsirolimus, SNS032, and
ponatinib, which were shown to decrease viability by
50 % or more (Fig. 1a).
BCR-ABLT315I-selective TKI, ponatinib, was capable of
inhibiting all three cell lines tested. KCL22-IR cells dem-
onstrated slightly higher cell viability levels in response
to individual treatments with the compounds tested, sug-
gesting an increased resistance to multiple kinase
inhibitors.
Karyotyping analysis was performed on KCL22-IR cells to
further characterize this CML drug-resistant cell line (Fig. 1b).
The results demonstrated an extensive abnormal karyotype
consisting of multiple structural and numerical aberrations
including the t(9;22) which was present with trisomy 6 and
tetrasomy 8. Karyotyping analysis also revealed the presence
of the Ph-positive chromosome as well as an additional
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chromosome22.With theexceptionof the specificnovelKCL22-IR
(50~54,X,del(X)(p11.4p22.2),dup(2)(p13p21),der(19)t(3;19)-(q25;-
q13.1), chromosomes identified by karyotyping analysis of the
KCL22-IR cell line are in agreement with prior karyotyping of a
previously described imatinib-resistantKCL22 cell line [14].
RT-PCR amplification followed by DNA sequencing of the
ABL kinase domain covering amino acids 236–486 was carried
out to identify novel somatic mutations within the BCR-ABL
kinasedomainofKCL22-IRcells (Fig.1c).Mutationof threonine
atposition315 to isoleucine (T315I)within theBCR-ABLkinase
domain was confirmed in approximately an equal amount to the
normal allele. Additionally, twominor variants were also detect-
ed. Variant one, c.1087_1088delGA, displayed a frameshift mu-
tation beginning at aspartate 363 and continued for 18 codons
resulting in a truncated protein. The clinical significance of this
mutation and whether it is responsible for imatinib resistance is
unknown.Variant two, a 35-base pair insertion occurring at the
junction of exon 8 and exon 9, was also detected and caused a
premature truncation of the protein within the BCR-ABL ki-
nase domain. Notably, two mutations, c.1423_1424ins35 and
c.1086_1270del, were present and amino acid variations are
shown to be p.C475YfsX11 and p.R362SfsX21, respectively.
Amino acid variant p.C475YfsX11 has been identified in pa-
tients known to have resistance towards multiple kinase inhib-
itors of BCR-ABL [15, 16]. However, the amino acid variant
R362SfsX21isnovel to theKCL22-IRcell lineandhasyet tobe
identified and investigated within the general population.
Lastly, in comparison to the K562 cell line, which
displayed 85 % cell apoptosis, the KCL22-IR cell line
displayed limited change in cell viability levels (Fig. 2a) or
apoptotic response (Fig. 2b), following 48-h treatment with
10 μM imatinib. Such findings are significant as the concen-
tration of imatinib is nearly ten times the approximated clini-
cally attainable value [17].
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Fig. 1 KCL22-IR cells contain the T315I BCR-ABL mutation and
demonstrate resistance towards multiple FDA-approved small molecule
kinase inhibitors. a Heat map representation of cell viability (% of
DMSO, Cntrl) in response to reported Cmax values of FDA-approved
compounds at 72 h in K562, KCL22-WT, andKCL22-IR cell lines, n = 3.
b Molecular cytogenetic karyotyping analysis of KCL22-IR cell line,
SKY type (top panel) and G-banded karyotyping (bottom panel).
C om p o s i t e k a r y o t y p e o f KCL 2 2 - I R i s a s f o l l o w s :
50~54,X,del(X)(p11.4p22.2),+der(1;10)(q10;p10),dup(2)(p13p21),+6,+
8 , + 8 , t ( 9 ; 2 2 ) ( q 3 4 ; q 1 1 . 2 ) , d e r ( 1 7 ; 1 9 ) ( q 1 0 ; q 1 0 ) , +
1 9 , d e r ( 1 9 ) t ( 3 ; 1 9 ) ( q 2 5 ; q 1 3 . 1 ) , i ( 2 1 ) ( q 1 0 ) , +
d e r ( 2 2 ) t ( 9 ; 2 2 ) [ c p 1 7 ] , 5 5 , i d e m , + 6 , + 8 [ 2 ] , 5 1 , i d e m , +
6,ad(6)(q13),der(18)t(5;18)(p13;p11.2). (c) Sequencing chromatograph
of KCL22-IR DNA highlighting the C > T substitution at nucleotide
position 944 on Exon 6 of the BCR-ABL kinase domain. The table lists
a brief description of mutations identified during DNA sequencing
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Forskolin and celastrol inhibit cell viability
within the T315I harboring KCL22-IR cell line
The KCL22-IR cell line was screened against a panel of
natural compounds, including celastrol and forskolin.
Celastrol has been previously identified to be a selective
inhibitor of heat shock protein 90 (Hsp90), which can lead
to the down regulation of multiple tyrosine kinases in-
cluding BCR-ABL [18]. Hsp90, a chaperone of BCR-
ABL and other major cell-signaling molecules, has
remained an attractive target for designing molecules ca-
pable of inhibiting multiple forms of cancer [19].
Recently, celastrol has been reported to induce apoptosis
and deplete BCR-ABL protein expression levels within
imatinib-resistant CML cells harboring the T315I muta-
tion [18]. Celastrol treatment (1 μM) of KCL22-IR cells
showed a ~50 % loss of cell viability when treated for 72-
h (data not shown). This concentration is more than 100-
fold the Cmax values reported in toxicology reports for
Sprague-Dawley rats treated with intravenous and oral
administration of pure celastrol [20]. Moreover, an IC50
value was attained at 72 h using the adenylate cyclase
activator, forskolin, at a concentration of 100 μM.
Importantly, this dose of forskolin is 50-fold less than
the reported LD50 concentrations tested in rats to be tol-














































Fig. 2 Increased resistance
towards high concentrations of
imatinib is observed within
KCL22-IR cell line. aMTS assay
showing comparison of cell
viability in K562 and KCL22-IR
cells treatedwith vehicle (DMSO)
or escalating doses of imatinib for
48 h. Error bars represent
standard deviation, n = 3. b FACS
analysis of cells treated with
vehicle (DMSO) or 10 μM
imatinib followed by staining
with propidium iodide and
Annexin V-FITC. K562 and
KCL22-IR cells treated for 48 h
as indicated. Annexin V-FITC
(horizontal axis) and propidium
iodide (vertical axis) staining was
performed to assess apoptosis
levels for each treatment, n = 3
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BCR-ABL signaling by activating protein phosphatase 2A
(PP2A) [22]. PP2A is a serine/threonine protein phospha-
tase that is important in regulating many cellular functions
and has been shown to be repressed in several cancer
types. Previous studies indicate BCR-ABL kinase activa-
tion induced the expression of the PP2A inhibitor, SET
[22]. These studies suggest that the effects of BCR-ABL
activation are reversible with forskolin treatment.
Synergistic inhibitory effect of ponatinib and forskolin
treatment on cell viability of CML cell lines
Since the KCL22-IR cell line displayed sensitivity to
single-agent treatments with ponatinib and forskolin,
combination efficacy with both drugs was investigated.
Utilizing the interaction index based on the Loewe
Additivity model, a highly synergistic combination of
ponatinib and forskolin was identified by varying the
doses as indicated in Fig. 3. Utilizing a non-constant-
ratio combination, keeping forskolin concentration set at
20 μM, CI values were obtained for five dose points, ranging
from 0.5 to 10 nM ponatinib. Results from this combination
resulted in CI values ranging from 0.309 to 0.688 (Fig. 3b). The
highest synergy was observed in KCL22-IR cells treated with a
combination of 2.5 nM ponatinib and 20μM forskolin (Fig. 3a,
b). These findings are important given that the IC50 values of
individual treatments are 20 nM ponatinib and 100 μM
forskolin in KCL22-IR cells.
To evaluate the synergistic effect of ponatinib and
forskolin treatment (abbreviated PF), parental KCL22
and K562 cells were employed. PF treatment displayed
synergistic activity against these CML cell lines; however,
synergistic activity remained prominent within the
KCL22-IR cell line (Fig. 3c). To ensure that PF treatment
specifically targeted BCR-ABL-positive cells, combina-
tional treatment was also tested against three non-mye-
loid, BCR-ABL-negative, leukemia cell lines. Cells tested
included the IL-3-dependent murine pro-B cell line, Baf3,
the IL-2-dependent human T cell line, Kit225, and the
human T cell lymphoma cell line, HH. The results indi-
cated that PF treatment did not impact the cell viability of
these three BCR-ABL-deficient leukemia cell lines
(Fig. 3d). Lastly, PF treatment was tested against human
primary naive and PHA-stimulated PBMCs to investigate
the off-target effects of treatment. Similar combinational
treatment was tested against two non-hematopoietic cells
lines, HepG2 and HEK293 (Fig. 3e). As shown in Fig. 3e,
there was no observable effect on cell viability following
combinational treatment suggesting that PF treatment is
se lec t ive for BCR-ABL-express ing CML cel ls .
Importantly, these results also suggest that PF combina-
tional treatment has limited off-target effects against non-
myeloid BCR-ABL-deficient cell types.
Ponatinib and forskolin combination modulates
KCL22-IR cell-signaling activity downstream
of BCR-ABL and does not regulate cell viability
through an apoptotic mechanism
To investigate the mechanism by which PF treatment induces
cell death within the KCL22-IR cell line, cells were treated
with ponatinib (2.5 nM), forskolin (20 μM), imatinib
(10 μM), or a combination of ponatinib (2.5 nM) with
forskolin (20 μM). Following a 4-h treatment, the phosphor-
ylation state of BCR-ABL remained unchanged regardless of
treatment conditions within the KCL22-IR cell line (Fig. 4a).
In addition, the common BCR-ABL substrate and linker pro-
tein CRK-L was shown to have unchanged phosphorylation
activity in response to PF treatment (Fig. 4a).
Utilizing the same treatment conditions mentioned above,
modulators of apoptosis were analyzed after 48-h treatment
with PF in KCL22-IR and K562 cell lines (Fig. 4b). Annexin
V/PI staining suggests that KCL22-IR cells displayed no ap-
optotic mechanism when exposed to these treatment condi-
tions. Additionally, within both cell lines, forskolin (20 μM)
alone was not sufficient to induce a significant amount of
Annexin V-positive cells. However, the K562 cell line did
demonstrate an apoptotic response to imatinib (10 μM) and
imatinib (10 μM) in combination with forskolin (20 μM).
These results suggest that forskolin alone is not sufficient for
inducing apoptosis within BCR-ABLT315I-positive CML
cells. Interestingly, ponatinib alone (2.5 nM) and PF combi-
national treatment induced apoptosis specifically in the K562
cell line but had no effect on KCL22-IR cells. To reconcile
these findings with previous results showing KCL22-IR cell
viability is reduced by PF treatment, we investigated the ef-
fects on cell cycle progression. Cell cycle analysis revealed
that PF treatment lead to an increase in the percentage of
KCL22-IR cells being arrested in the G1 phase in comparison
to KCL22 parental and K562 cell lines. Cell cycle arrest with-
in G1 phase was seen in all three cell lines (Fig. 4c).
To determine whether a 24-h PF treatment had any effect
on KCL22-IR signal transduction, the phosphorylation status
of multiple targets within various signaling pathways was in-
vestigated. After a 24-h PF treatment, apoptosis associated
proteins (PARP, Caspase-3, JNK, BCL-2, AKT, Caspase-9,
p53, and Caspase-8) showed no significant response to treat-
ment compared to vehicle alone (Fig. 5a). BCL-2 associated
death promoter (BAD) showed a significant increase in acti-
vation in response to PF treatment in comparison to ponatinib
treatment alone (Fig. 5a); however, we note that forskolin
treatment alone was sufficient to elevate BAD phosphoryla-
tion. As reported earlier, cell viability assays suggest that the
concentrations of forskolin used in this study do not signifi-
cantly alter cell viability within the KCL22-IR cell line.
Based on these findings, SFKs were also analyzed as
shown in Fig. 5b, as a possible explanation for reduced cell
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viability following PF treatment. SRC kinase activity was
greatly disrupted by PF treatment when compared to individ-
ual treatment of imatinib, ponatinib, forskolin, or the combi-
nation of imatinib and forskolin. Indeed, reduced tyrosine
phosphorylation in response to PF treatment was observed
for SRC, LCK, and LYN kinase activation profiles (Fig. 5b).
Lastly, various substrates that serve important roles in
maintaining cell survival, gene transcription, and cell
growth were analyzed (Fig. 5c). STAT3 activation was
found to be significantly decreased in KCL22-IR cells
following PF treatment. In summary, activated forms of
LYN-, SRC-, and LCK kinases as well as STAT3 were
decreased in response to combinational PF treatment,
suggesting that these intermediates are vital players in
maintaining cell viability and cell cycle progression
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Fig. 3 Ponatinib and forskolin combinational treatment shows synergy
in KCL22-IR cells and selectivity for CML cell lines. a Constant-ratio
(1:10,000) combination index plot demonstrating synergistic activity
between ponatinib and forskolin treatment by varying ponatinib
between 0.5 and 10 nM and forskolin from 5 to 10 μM. The interaction
index based on the Loewe Additivity model was used. Values <1, =1, or
>1 indicate synergy, additive effect, or antagonism, respectively. b Non-
constant-ratio combination index plot highlighting 20 μM forskolin
maintains synergy with ponatinib at concentrations between 0.5 and
10 nM. c CML cell lines K562, KCL22-WT, and KCL22-IR were
treated with increasing concentrations of ponatinib, as indicated, in
combination with 20 μM forskolin, n = 3. d Non-BCR-Abl-expressing
leukemic cell lines including HH, Baf3, and Kit225 cells were treated
with combinational therapy of increasing ponatinib concentrations, as
indicated, plus 20 μM forskolin, n = 3. e Naïve PBMCs, PHA-activated
PBMCs, or non-lymphoid tissue cells lines HEPG2 and HEK-293 treated
with increasing concentrations of ponatinib, as indicated, plus 20 μM
forskolin, n = 3
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Fig. 4 Ponatinib and forskolin treatment regulate cell cycle progression
of KCL22-IR cells. a KCL22-IR cells were treated with 2.5 nM
ponatinib, 10 μM imatinib, and 20 μM forskolin, for 4 h. KCL22-IR cell
lysate was separated by SDS-PAGE and Western blotted for
phosphotyrosine (pY) cABL, total cABL, pY-CRK-L, and total CRK-
L, representative image of n = 3. b Apoptosis panel of K562 and
KCL22-IR cells treated for 48 h with vehicle (DMSO), imatinib,
ponatinib, forskolin as indicated, combinational treatments of imatinib
(10 μM) plus forskolin (20 μM), or ponatinib (2.5 nM) plus forskolin
(20 μM). Annexin V-FITC (horizontal axis) and propidium iodide
(vertical axis) staining was performed to assess apoptosis levels for
each treatment, n = 3. c KCL22-WT, KCL22-IR, and K562 cells were
subjected to similar treatment as above for 24, 48, 72, and 96 h. Entropy
measurements are shown for each time point, n = 3. Analysis for each
time point utilizing 0.01 level of significance to control for multiple
comparisons at four time points (Bonferroni correction used). Graphs
display drug response as a measurement of entropy. As percentage of
cells shift towards a specific cell cycle phase (amount of cells within
G1 phase) entropy decreases, allowing for identification of area of cell
cycle arrest (P < 0.005)
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Discussion
The imatinib-resistant BCR-ABLT315I mutation in CML has
been associated with decreased overall survival rates
when compared to non-mutation possessing patients
[23]. Ponatinib has demonstrated potent efficacy in drug-
resistant forms of CML, including those harboring the
T315I mutation; however, ponatinib has proven to be
toxic at high concentrations [11, 24]. Overcoming this
clinical barrier could entail exploring new strategies to
elicit ponatinib efficacy at lower concentrations, such as
those described in this study. Combination treatment of
ponatinib and forskolin reduced individual IC50 values
by approximately 40-fold with respect to the observed
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Fig. 5 Ponatinib and forskolin treatment of KCL-22-IR cells modulates
LYN kinase and STAT3 activation. a Multiplex analysis of apoptosis
associated proteins in KCL22-IR cells treated with vehicle (DMSO),
ponatinib (2.5 nM), imatinib (10 μM), forskolin (20 μM),
combinational treatments of imatinib (10 μM) plus forskolin (20 μM),
or ponatinib (2.5 nM) plus forskolin (20 μM) for 24 h. MFI (median
fluorescence intensity) is plotted (y-axis) for mean values of three
independent tests, n = 3. b Multiplex analysis of activation status of
SFK tyrosine kinase family members in KCL22-IR cells treated as
described above, n = 3. c Multiplex analysis of phosphorylation status
of multiple signal transduction proteins after treatment of KCL22-IR cells
as described above. Error bars indicate standard deviation, n = 3;
statistical relevance indicated as p < 0.01 (single asterisk); p < 0.001
(double asterisk)
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In vitro studies have revealed that IC50 levels of ponatinib
require doses of approximately 8 nM, while most drug-
resistant CML cell lines require 30 nM ponatinib to be effec-
tive [9]. The data presented in this study suggest that ponatinib
IC50 values can be reduced to 0.5 nM when used in combina-
tion with forskolin at a concentration of 20 uM. Within the
KCL22-IR cell line, treatments with 20 nM ponatinib or
100 μM forskolin individually, were required to obtain any
inhibitory effect (data not shown). This synergistic activity
may be due to altered BCR-ABL regulation as forskolin is
known to induce activation of the phosphatase PP2A, which
regulates BCR-ABL activity through activation of SHP1 [22].
It is tempting to speculate that the effects observed may be
attributed to two potential mechanisms by which PF treatment
inhibits BCR-ABL. First, BCR-ABL inhibition is generated
by the direct binding of ponatinib within the BCR-ABL ATP
binding site. Second, forskolin induces the activation of PP2A
which inhibits BCR-ABL activity directly. It is worth noting
that ponatinib possesses unique properties to effectively inhib-
it the BCR-ABL protein in the presence or absence of the
T315I mutation [7].
Based upon the selectivity profiles of each inhibitor
assessed in the reported drug screen, several candidate cell-
signaling pathways were postulated to be activated. Potential
signaling pathways that may be activated within the KCL22-
IR cell line include BCR-ABLT315I, mammalian target of
rapamycin (mTOR), mitogen-activated protein kinase (MEK
1/2), and cyclin-dependent kinase (CDK) 9/2/7 pathways.
Various groups have reported that BCR-ABL activity may
directly or indirectly modulate multiple signaling pathways
including PI3K/AKT and RAS/RAF/MEK/ERK pathway
[25]. However, when utilizing TKIs, RTK activity was not
critical for cell survival within the KCL22-IR cell line.
Furthermore, the results described in this study suggest a nov-
el approach for treating drug resistant CML cases by
exploiting an observed synergistic activity between ponatinib
in combination with forskolin. To the best of our knowledge,
this is the first time ponatinib and forskolin have been inves-
tigated for the treatment of drug-resistant CML in vitro, and
such a synergistic approach is yet to be tested in patients with
T315I-positive CML. The results observed here may be indic-
ative of forskolin’s ability to reactivate the known negative
regulator of BCR-ABL, protein phosphatase PP2A [22].
Forskolin has been used globally as a natural herb to treat
cardiovascular ailments, skin disorders, hypertension, and
other disorders [26]. In addition, forskolin has been clinically
evaluated for its therapeutic properties in treating and
preventing asthma attacks and has been shown to demon-
strate a similar effectiveness when compared to widely used
glucocorticoid steroids such as beclomethasone [27].
Combination treatment involving the usage of ponatinib
and forskolin may provide a unique opportunity to directly
or indirectly target BCR-ABL. This novel treatment strategy
may ultimately be a viable option for managing T315I-
positive CML cells at lower doses of ponatinib than those
currently employed in the clinic.
Current ponatinib treatment has been linked to a significant
riskof cardiac toxicity andvascular adverse events (VAEs), such
as blood clots, cardiac arrhythmias, congestive heart failure, and
myocardial infarction [24]. Indeed, such VAEs have been asso-
ciated with multiple TKIs, including imatinib [12]. Based upon
the results presented herein, further investigation into the new
therapeutic strategy inwhichacombinationofponatiniborother
TKIs are used in combination with forskolin is warranted.
Forskolinandponatinibdemonstratedasynergistic combination
andmechanistic effect onBCR-ABLpathways thatmay reduce
the progression ofCMLwithout the risk attributed toVAEs.The
results presented in this study identified an imatinib-resistant
T315I BCR-ABLCML cell line, KCL-22IR, whose growth
couldbesynergistically inhibitedwithclinicallyattainable levels
of ponatinib and forskolin, thereby representing a novel thera-
peutic strategy to treat this drug-resistant type of CML.
Materials and Methods
Cell culture and establishment of imatinib-resistant cell
line
The following cell lines, KCL22 (parental and IR), K562,
HH, and human peripheral blood mononuclear cells
(PBMCs) were maintained using complete RPMI-1640
media (HyClone) containing 10 % fetal bovine serum
(FBS, At lanta Biologicals) , 2 mM L-glutamine
(Corning), 50 mg/ml penicillin-streptomycin (Corning).
Kit225 and Baf3 cell lines were maintained in complete
RPMI-1640 media supplemented with 100 IU/ml IL-2 or
100 IU/ml IL-3, respectively. HEK293 and HepG2 cells
were maintained in DMEM high glucose (HyClone,) con-
taining 10 % FBS, 2 mM L-glutamine and 50 mg/ml
penicillin-streptomycin. The imatinib-resistant cell line
was developed by maintaining parental KCL22 cells in
culture with imatinib concentrations of 500 nM,
750 nM, or 1 μM during weeks 1–2, weeks 3–4, and
weeks 4–6, respectively. During this 6-week period,
KCL22 cells were passaged at 40 % of the standing pop-
ulation and imatinib concentrations replenished every
3 days. Cell population number was consistently main-
tained between 5 and 10 million cells per milliliter.
Drug treatments
Clinically observed peak drug exposure concentrations
(Cmax), obtained from literature regarding phase I evalua-
tions, were used for generating appropriate in vitro dose
curves for each kinase inhibitor. Cmax values for each kinase
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inhibitor were as follows: imatinib (4478.0 ng/ml) [17], gefi-
tinib (443.88 ng/ml) [28], dasatinib (46 ng/ml) [29], sunitinib
(70.9 ng/ul) [30], erlotinib (1737 ng/ul) [31], lapatinib
(2470 ng/ul) [32], nilotinib (1906.27 ng/ml) [33], sorafenib
(2248 ng/ul) [34], trametinib (33.4 ng/ml) [35], and
vemurafenib (61 μg/ml) [36].
Cell viability assays
Cells were cultured in complete media (described above) in
the absence or presence of the respective Cmax concentration
determined for each respective drug dose curve. Cells were
seeded at a concentration of 1.0 × 104 cells per well in a 96-
well plate. Culture plates were kept in incubation at 37 °C, 5%
CO2 for 72-h. After 72-h, CellTiter96 MTS Reagent
(Promega) was used according to manufacture instructions.
Absorbance was recorded at 490 nm using a 96-well plate
reader.
Cell apoptosis screening
To investigate whether disruption of cellular membrane
integrity is involved as a mechanism of cell death, cells
were analyzed via flow cytometry. Cells were stained uti-
lizing Annexin V-FITC and PI (Promega). Cells were
seeded in 24-well plates at a density of 100,000 cells
per well in 2 ml of culture media. Compounds used in
the apoptosis screen were imatinib (10 μM), ponatinib
(2.5 nM), forskolin (20 μM), imatinib with forskolin (10
and 20 μM, respectively), ponatinib with forskolin (2.5
and 20 μM, respectively), DMSO was used as a negative
control, and H2O2 (10 μM) was used as a positive control.
Cells were kept in culture with individual treatments for
48 h, after which were harvested and suspended in cold
1X PBS. Cells were stained according to the manufactures
instructions. Briefly, staining consisted of placing cells in
100 μl of cold binding buffer containing a mixture of
Annexin V-FITC and PI for 15 min. Cells were analyzed
via flow cytometry using a Cytomics FC 500 (Beckman
Coulter).
Luminex analysis of cell-signaling proteins
Protein expression and phosphorylation status were analyzed
utilizing a Luminex 100 System (Austin, TX). Milliplex as-
says were obtained from Millipore, Billerica, MA, USA.
Assays used included the following: 9-Plex MultiPathway
Panel for phosphorylated ERK/MAP kinase 1/2 (Thr185/
Tyr187), Akt (Ser473), STAT3 (Ser727), JNK (Thr183/
Tyr185), p70 S6 kinase (Thr412), NF-κB (Ser536),
STAT5A/B (Tyr694/699), CREB (Ser133), and p38
(Thr180/Tyr182); 8-Plex Src Family Kinase Panel for phos-
phorylated Blk (Tyr389), Fgr (Tyr412), Fyn (Tyr420), Hck
(Tyr411), Lck (Tyr394), Lyn (Tyr397), Src (Tyr419), and
Yes (Tyr421); 3-Plex Apoptosis Panel for activated
Caspase3, total GAPDH, and cleaved PARP; and 7-Plex
Early Apoptosis Panel for Akt (Ser473), BAD (Ser112),
Bcl-2 (Ser70), Active Caspase 8 (Asp384), Active Caspase 9
(Asp315), and JNK (Thr183/Tyr185), p53 (Ser46). Cells were
lysed, and luminex plates were prepared and analyzed accord-
ing to manufacture instructions.
Solubilization of proteins, electrophoresis, and Western
blot analysis
1.0 × 106 cells were treated for 4 h as indicated, lysed, and
protein quantified as previously described [37]. Equal concen-
trations of protein were subjected to SDS-PAGE electropho-
resis and protein transferred to PVDFmembrane as previously
described [37]. Antibodies to cAbl (K-12, Santa Cruz
Biotechnology), Crk-L (C-20, Santa Cruz Biotechnology),
and phosphotyrosine (4G10, Millipore) were used for
Western blotting. All antibodies were used according to man-
ufactures suggested protocols. Western blots were developed
with horseradish peroxidase-conjugated goat anti-mouse IgG
(heavy plus light chain, KPL) or goat anti-rabbit IgG (heavy
plus light chain, KPL) and visualized using enhanced chemi-
luminescence and x-ray film.
Drug synergy calculation and statistics
Under the assumption that the dose-effect curves follow
Chou-Talalay’s median effect equation [38], Lee and Kong
(2009) provide analytic expressions and software for calculat-
ing the confidence interval for the estimated interaction index
[39]. Drug synergy was determined by use of the CI of
Interaction Index software which can be downloaded from
http:/biostatistics.mdanderson.org/SoftwareDownload/. The
interaction index was calculated using the four doses on the
fixed-ray design according to Lee and Kong (2009) and for
combination doses according to Lee and Kong (2009).
According to the Loewe Additivity model, interaction index
(CI) values <1, =1, or >1 represent synergy, additive effect, or
antagonism, respectively [38].
Cell cycle phase entropy calculation
Let pi denote the proportion of cells found in the ith phase of a




where the sum is over all phases of the cell cycle. An entropy
of zero indicates that the cells are all in one phase of the cell
cycle. Maximum entropy occurs when the proportion of cells
in each cell cycle phase is the same.
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G-banding and spectral karyotyping and BCR-ABL
kinase domain mutation analysis
KCL22-IR cells were sent to WiCell Research Institute,
Madison, WI, USA, for G-banding and spectral karyotyping
(SKY) analysis. Qiagen DNeasy Blood & Tissue Kit was used
to purify genomic DNA from KCL22-IR cells according to
manufactures protocol. DNA concentration was measured
using NanoDrop 3000 (Thermo Fisher Scientific), and was
verified using 1 % agarose gel (Ultra-pure Agarose with 1×
TBE) containing 0.002 % ethidium bromide. KCL22-IR ge-
nomic DNA was sent to the Blood Center of Wisconsin,
Milwaukee, WI, USA, for identification of DNA variants
within the ABL kinase domain by RT-PCR followed by
DNA sequence analysis of ABL kinase domain covering ami-
no acids 236–486.
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